Overview

Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects

Status:
Completed
Trial end date:
2021-11-15
Target enrollment:
Participant gender:
Summary
A randomized, open label, single dose, balanced, two treatment, two sequence, four period, fully replicate, cross over bioequivalence study under fasting condition.
Phase:
Phase 1
Details
Lead Sponsor:
Abbott
Treatments:
Budesonide